What Is PT-141? A Complete Scientific Guide

PT-141, more formally known as bremelanotide, is a synthetic peptide developed for research into sexual desire and arousal.

Unlike medicines such as sildenafil, which mainly influence blood flow, bremelanotide acts primarily through signalling pathways in the brain.

It belongs to a class of compounds known as:

Melanocortin receptor agonists

Research suggests that bremelanotide influences neural pathways involved in:

• Sexual desire

• Motivation

• Arousal

• Reward

• Reproductive behaviour

Bremelanotide is also the active ingredient in Vyleesi, a prescription medicine approved by the US Food and Drug Administration in 2019 for a narrowly defined group of premenopausal women with acquired, generalised hypoactive sexual desire disorder.

The FDA indication does not include:

• Men

• Postmenopausal women

• General sexual-performance enhancement

• Erectile dysfunction

• Sexual difficulties caused by medication

• Relationship-related low desire

• Low desire caused by another medical or psychiatric condition

It is not an authorised medicine in the United Kingdom.

Although bremelanotide has undergone more human clinical research than many experimental peptides, online claims often extend well beyond its approved US indication and the available evidence.

This guide examines what PT-141 is, how it works, what clinical trials have shown, its potential effects in women and men, and its major safety limitations.

PT-141 quick facts

The FDA approved Vyleesi on 21 June 2019 for acquired, generalised hypoactive sexual desire disorder in selected premenopausal women.

What is PT-141?

PT-141 is the research-development name commonly used for bremelanotide.

Bremelanotide is a synthetic cyclic peptide derived from research involving the melanocortin system.

Its cyclic structure means that part of the peptide forms a ring.

Cyclisation can affect:

• Molecular stability

• Receptor binding

• Resistance to enzymatic breakdown

• Duration of biological activity

Bremelanotide activates several melanocortin receptors, with its effects on sexual behaviour believed to involve primarily the MC3 and MC4 receptors within the central nervous system.

What is bremelanotide?

Bremelanotide is the formal generic name for PT-141.

The two names refer to the same active compound, although commercial research products labelled PT-141 should not automatically be assumed to match the purity, formulation or concentration of an approved bremelanotide medicine.

The FDA-approved product is supplied as a prefilled subcutaneous autoinjector containing 1.75 mg in 0.3 mL.

This does not mean that unregulated PT-141 products are medically equivalent to Vyleesi.

How was PT-141 developed?

PT-141 was developed from research involving melanotan II, another synthetic melanocortin peptide.

Melanotan II was initially investigated for its effects on skin pigmentation.

During early research, investigators observed unexpected sexual responses, including spontaneous erections in some male participants.

This led researchers to isolate and develop a related compound intended to retain sexual-response effects while reducing pigmentation-related activity.

That compound became PT-141, or bremelanotide.

What is the melanocortin system?

The melanocortin system is a network of peptides and receptors involved in numerous biological functions.

These include:

• Pigmentation

• Appetite

• Energy balance

• Inflammation

• Sexual behaviour

• Stress responses

• Cardiovascular regulation

Naturally occurring melanocortins are produced from the precursor protein:

Pro-opiomelanocortin, or POMC

POMC-derived peptides include:

• ACTH

• Alpha-MSH

• Beta-MSH

• Gamma-MSH

These peptides act through five known melanocortin receptors:

• MC1R

• MC2R

• MC3R

• MC4R

• MC5R

Bremelanotide does not activate all these receptors equally.

Which receptors does PT-141 activate?

Bremelanotide is described as a non-selective melanocortin receptor agonist.

It has activity at several melanocortin receptors but does not meaningfully activate MC2R, the ACTH receptor responsible for stimulating adrenal cortisol production.

Its sexual effects are believed to involve mainly:

• MC3R

• MC4R

These receptors are expressed in brain regions involved in:

• Sexual motivation

• Reproductive behaviour

• Autonomic responses

• Reward processing

• Appetite regulation

The complete mechanism behind bremelanotide’s clinical effects has not been fully established.

PT-141 and MC4R

MC4R is widely expressed within the central nervous system.

It plays established roles in:

• Appetite

• Energy expenditure

• Body-weight regulation

• Autonomic signalling

• Sexual behaviour

Activation of MC4R is thought to contribute to bremelanotide’s effects on sexual desire and arousal.

However, MC4R activation can also influence blood pressure and other autonomic functions, which helps explain some of the medicine’s safety concerns.

PT-141 and MC3R

MC3R is involved in energy balance, metabolic regulation and neural signalling.

Its precise role in human sexual behaviour is less clearly defined than that of MC4R.

Animal experiments suggest that both MC3R and MC4R pathways may contribute to melanocortin-related sexual responses.

It remains difficult to assign bremelanotide’s clinical effects to one receptor alone.

Does PT-141 increase dopamine?

Bremelanotide does not act as a conventional dopamine agonist.

However, melanocortin receptor activation may influence downstream dopamine pathways involved in:

• Motivation

• Reward

• Sexual interest

• Behavioural activation

FDA chemistry-review documents describe a proposed mechanism in which MC4R activation influences hypothalamic dopamine activity and sexual desire.

This remains a simplified model rather than a complete explanation of its effects.

Is PT-141 a hormone?

No.

PT-141 is a synthetic peptide and melanocortin receptor agonist.

It does not directly replace:

• Testosterone

• Oestrogen

• Progesterone

• Oxytocin

• Dopamine

It may influence brain pathways associated with sexual response without substantially increasing sex-hormone concentrations.

PT-141 and sexual desire

Bremelanotide was specifically developed to influence sexual desire rather than simply improve genital blood flow.

Human trials have measured outcomes including:

• Sexual desire

• Distress related to low desire

• Sexual arousal

• Frequency of satisfying sexual events

• Patient-reported treatment benefit

Two phase III trials, known collectively as the RECONNECT studies, reported statistically significant improvements in sexual desire and reductions in distress associated with low desire in premenopausal women with HSDD.

The size and clinical importance of the average benefit have nevertheless been debated. One clinical review described the overall clinical benefit as potentially modest, while later methodological critiques questioned aspects of the trial outcome measures.

What is hypoactive sexual desire disorder?

Hypoactive sexual desire disorder, or HSDD, describes persistently reduced sexual desire that causes significant personal distress.

A diagnosis requires more than simply having a lower libido than a partner or experiencing normal fluctuations in sexual interest.

Low desire should not be better explained by:

• Another medical condition

• A psychiatric condition

• Relationship difficulties

• Medication effects

• Substance use

• Temporary stress

• Pregnancy or postpartum changes

Bremelanotide’s US indication is specifically limited to acquired, generalised HSDD in premenopausal women whose symptoms are not caused by these other factors.

What does acquired HSDD mean?

“Acquired” means the low desire developed after a previous period of satisfactory sexual desire.

It does not refer to someone who has experienced low desire throughout their entire sexual life.

What does generalised HSDD mean?

“Generalised” means the low desire occurs:

• Across partners

• Across situations

• Across forms of sexual activity

It is not limited to one relationship, situation or type of stimulation.

FDA approval

The FDA approved Vyleesi in June 2019.

The approved indication is:

Acquired, generalised HSDD in premenopausal women whose low sexual desire causes marked distress or interpersonal difficulty and is not caused by a medical or psychiatric condition, relationship problems, medication or drug use.

The FDA label specifically states that it is not indicated:

• For postmenopausal women

• For men

• To enhance sexual performance

Is PT-141 approved in the UK?

Bremelanotide is not an authorised medicine in the United Kingdom.

It should therefore not be described on a UK research website as an approved libido treatment.

FDA approval in the United States does not automatically provide:

• MHRA approval

• UK prescribing authorisation

• UK marketing authorisation

• Approval for unlicensed commercial PT-141 products

PT-141 clinical trials in women

The RECONNECT clinical programme included two similarly designed phase III trials.

Participants were premenopausal women with acquired, generalised HSDD.

The studies compared bremelanotide with placebo over approximately 24 weeks.

The co-primary outcomes evaluated:

• Changes in sexual desire

• Changes in distress related to low sexual desire

The trials reported statistically significant improvement in both measures.

However, the increase in satisfying sexual events did not form the basis of the FDA-approved efficacy conclusion, and the average magnitude of benefit was not dramatic.

The most scientifically balanced conclusion is that bremelanotide produced a measurable benefit for some women, but responses varied and the average effect was modest.

Long-term evidence

Participants from the phase III trials could enter a 52-week open-label extension.

The extension reported sustained symptom improvements and no new major safety signal.

However, open-label studies have important limitations because:

• Participants know they are receiving the active treatment.

• There may be no continuing placebo comparison.

• People who did not tolerate or benefit from treatment may be more likely to withdraw.

• Expectation can influence subjective outcomes.

The extension was funded by companies involved in bremelanotide’s development.

Does PT-141 increase satisfying sexual events?

The phase III trials did not demonstrate a strong improvement in every sexual outcome measured.

This distinction matters because:

• Desire scores may improve without more frequent sexual activity.

• Reduced distress is not identical to increased arousal.

• Improved arousal is not identical to orgasm.

• Clinical benefit may differ considerably between individuals.

Bremelanotide should not be described as guaranteeing increased sexual activity or satisfaction.

PT-141 and female sexual arousal

Earlier phase II research included women with HSDD and female sexual arousal disorder.

Some studies reported improvements in patient-reported desire and arousal measures.

However, the eventual FDA indication was limited to HSDD rather than every form of female sexual dysfunction.

Female sexual difficulties may result from:

• Menopause

• Vaginal dryness

• Pelvic pain

• Endometriosis

• Medication

• Trauma

• Relationship distress

• Depression

• Hormonal changes

• Neurological disease

A central desire-targeting medicine may not address these underlying causes.

PT-141 and low libido in postmenopausal women

The FDA-approved indication does not include postmenopausal women.

Low desire after menopause may involve:

• Reduced oestrogen

• Genitourinary syndrome of menopause

• Vaginal discomfort

• Sleep disruption

• Medication effects

• Relationship factors

• Changes in androgen signalling

• Chronic illness

Evidence for bremelanotide in this population remains insufficient for an approved indication.

PT-141 and men

PT-141 has been investigated experimentally in men, particularly in relation to erectile responses.

However, it is not FDA approved for men.

Male sexual dysfunction may involve:

• Vascular disease

• Diabetes

• Low testosterone

• Neurological disease

• Medication

• Anxiety

• Relationship factors

• Pelvic surgery

• Sleep disorders

PT-141 should not be presented as a proven general treatment for male sexual dysfunction.

PT-141 and erections

Melanocortin receptor activation may produce erectile responses through central nervous-system pathways.

This differs from phosphodiesterase-5 inhibitors, which act largely by increasing blood flow within erectile tissue.

Early studies of melanocortin compounds reported spontaneous erections in some men.

Bremelanotide has therefore been investigated for erectile dysfunction, including in people with an inadequate response to sildenafil.

However, the evidence was not sufficient to obtain approval for male erectile dysfunction.

PT-141 vs sildenafil

PT-141 and sildenafil act through different pathways.

They are not interchangeable.

PT-141 and tadalafil

Tadalafil is another PDE5 inhibitor used for erectile dysfunction.

Like sildenafil, it acts primarily on vascular signalling rather than directly increasing sexual desire.

There is insufficient high-quality evidence establishing the safety and effectiveness of combining tadalafil with unregulated PT-141 products.

Does PT-141 increase testosterone?

Bremelanotide is not established as a testosterone-raising treatment.

Its main effects appear to occur through central melanocortin pathways rather than by stimulating the hypothalamic–pituitary–gonadal axis.

It should not be used as a substitute for investigating:

• Low testosterone

• Pituitary disease

• Testicular disease

• Hyperprolactinaemia

• Thyroid disorders

Does PT-141 increase oestrogen?

There is no established clinically significant oestrogen-raising effect.

Its approved use does not depend on directly replacing or increasing oestrogen.

PT-141 and orgasm

PT-141 is sometimes promoted as an orgasm-enhancing peptide.

Clinical trials focused primarily on sexual desire and distress.

Although improved desire or arousal could indirectly affect orgasm for some individuals, bremelanotide has not been proven to guarantee:

• Faster orgasm

• Stronger orgasm

• Multiple orgasms

• Resolution of anorgasmia

Difficulty reaching orgasm may have distinct neurological, medication-related, hormonal or psychological causes.

PT-141 and antidepressant-related sexual dysfunction

SSRIs and other antidepressants may cause:

• Reduced libido

• Delayed orgasm

• Erectile dysfunction

• Reduced genital sensation

The FDA indication specifically excludes low desire caused by a medication or drug substance.

Evidence is insufficient to establish PT-141 as a standard treatment for antidepressant-induced sexual dysfunction.

Changing psychiatric medication without medical supervision may cause relapse or withdrawal symptoms.

PT-141 and menopause

PT-141 does not replace oestrogen or treat the broader symptoms of menopause.

It would not be expected to directly correct:

• Vaginal tissue thinning

• Vaginal dryness

• Hot flushes

• Bone loss

• Menopausal sleep disturbance

Low desire caused by painful sex or vaginal dryness may require a different treatment approach.

PT-141 and relationship-related low desire

The approved indication excludes low desire caused primarily by relationship difficulties.

Sexual desire is influenced by:

• Emotional safety

• Attraction

• Conflict

• Communication

• Stress

• Fatigue

• Privacy

• Relationship satisfaction

A pharmacological treatment may not resolve these factors.

PT-141 and sexual-performance enhancement

Bremelanotide is not approved to improve sexual performance in people without a diagnosed sexual-desire disorder.

The FDA label explicitly excludes general performance enhancement.

Claims that PT-141 reliably increases performance in healthy men or women go beyond the approved evidence.

How is bremelanotide administered clinically?

The FDA-approved product is administered by subcutaneous injection.

It is intended for use when needed rather than as a daily medicine.

The authorised US product has specific limits on:

• Frequency

• Number of monthly doses

• Duration before assessing effectiveness

• Cardiovascular suitability

These prescribing instructions apply to the approved medicine and should not be converted into instructions for unregulated research products.

Why is dosing frequency limited?

Bremelanotide can cause temporary increases in blood pressure and reductions in heart rate.

Frequent exposure also increases the cumulative risk of focal hyperpigmentation.

The FDA label therefore limits repeated use and advises discontinuation when meaningful benefit is not achieved.

Blood-pressure effects

Bremelanotide can temporarily increase blood pressure.

The increase usually occurs after administration and later returns towards baseline.

Because of this effect, the approved product is contraindicated in people with:

• Uncontrolled hypertension

• Known cardiovascular disease

The FDA concluded that blood-pressure risks could be addressed through product labelling rather than a formal risk-management programme.

This cardiovascular warning is one of the most important distinctions between controlled medical use and informal peptide use.

PT-141 and heart rate

A temporary reduction in heart rate may accompany the rise in blood pressure.

The interaction between blood pressure, heart rate and autonomic signalling may vary between individuals.

People with cardiovascular disease were not the intended population for general unsupervised exposure.

Nausea

Nausea is the most commonly reported adverse effect of bremelanotide.

In the phase III programme, nausea was frequent and was one of the main reasons some participants discontinued treatment.

Nausea may be accompanied by:

• Vomiting

• Headache

• Flushing

• Reduced appetite

• Dizziness

The development programme included further investigation into nausea and the use of anti-nausea medication.

Hyperpigmentation

Bremelanotide can cause darkening of the skin.

Reported areas include:

• Face

• Gums

• Breasts

• Other localised skin regions

This is known as focal hyperpigmentation.

The risk appears greater with repeated exposure and in people with darker skin pigmentation.

Some pigmentation changes may not fully resolve after treatment is stopped.

This effect is biologically plausible because melanocortin receptors are also involved in pigment regulation.

Headache and flushing

Commonly reported adverse reactions include:

• Headache

• Flushing

• Injection-site reactions

• Vomiting

• Cough

• Fatigue

• Dizziness

• Nasal symptoms

Most trial adverse events were described as mild or moderate, but tolerability varied.

Serious adverse effects

The clinical programme did not identify a large rate of serious drug-related adverse events.

However, this does not mean that all PT-141 exposure is low risk.

Safety concerns may increase when:

• Product identity is uncertain.

• Concentration is inaccurate.

• Cardiovascular screening is absent.

• Doses are repeated frequently.

• Multiple sexual-function drugs are combined.

• The compound is used in populations not included in trials.

PT-141 and cardiovascular disease

Bremelanotide is not appropriate for people with established cardiovascular disease under its FDA label.

Potentially relevant conditions include:

• Coronary artery disease

• Previous heart attack

• Previous stroke

• Serious arrhythmia

• Uncontrolled hypertension

• Significant vascular disease

Sexual activity itself can also place temporary demands on the cardiovascular system.

PT-141 and blood-pressure medication

There is insufficient evidence to assume that blood-pressure medication completely removes bremelanotide’s cardiovascular risk.

Bremelanotide may also slow gastric emptying and could affect the absorption of certain oral medicines.

People taking cardiovascular medication require individual clinical assessment.

Delayed gastric emptying

Bremelanotide may slow gastric emptying.

This can potentially alter the rate at which some oral medicines are absorbed.

This is particularly important for medicines that require:

• Rapid onset

• Precise timing

• Consistent blood concentrations

The interaction may be clinically important even when the peptide does not directly alter the medicine’s metabolism.

PT-141 and oral contraceptives

Because bremelanotide may delay gastric emptying, there is a theoretical possibility of altered absorption of oral medicines.

The significance for any particular oral contraceptive depends on the formulation and timing.

There is insufficient evidence to give universal reassurance about unregulated PT-141 use alongside oral contraception.

PT-141 and alcohol

A phase I study evaluated bremelanotide with ethanol and did not identify a major new serious safety signal under the controlled conditions studied.

This does not prove that combining PT-141 with alcohol is always safe.

Alcohol may independently affect:

• Blood pressure

• Judgement

• Sexual decision-making

• Nausea

• Dehydration

• Consent

• Erectile function

PT-141 and sildenafil combination

Because the compounds act through different pathways, researchers and commercial users have shown interest in combining them.

However, robust clinical evidence establishing the safety of combining unregulated PT-141 with sildenafil is limited.

Potential concerns include:

• Blood-pressure changes

• Headache

• Flushing

• Dizziness

• Nausea

• Cardiovascular stress

• Priapism

Combination use should not be described as established or risk-free.

Priapism risk

Priapism is an erection lasting several hours that does not resolve normally.

It can damage erectile tissue and requires urgent treatment.

Although bremelanotide is not a conventional direct vasodilator, prolonged erections are a possible concern when compounds affecting sexual response are used, particularly in combination.

An erection lasting four hours requires emergency medical assessment.

PT-141 and pregnancy

Bremelanotide is not intended for use during pregnancy.

Its clinical purpose is unrelated to pregnancy, and animal reproductive data have raised concerns about fetal harm at certain exposures.

People who may become pregnant require appropriate medical guidance.

Naturally occurring melanocortin signalling does not prove that externally administered bremelanotide is safe during pregnancy.

PT-141 and breastfeeding

There is insufficient evidence to establish safety during breastfeeding.

It is uncertain whether bremelanotide or biologically active metabolites pass into human milk.

PT-141 and fertility

Bremelanotide is not a fertility treatment.

Increasing sexual desire does not necessarily improve:

• Ovulation

• Sperm production

• Egg quality

• Implantation

• Pregnancy rates

• Live-birth rates

Low desire and infertility are separate clinical issues, although they may sometimes coexist.

PT-141 and cancer

There is no established evidence that PT-141 treats cancer.

Because melanocortin receptors are expressed in several tissues and influence diverse biological pathways, long-term effects in people with active cancer remain insufficiently characterised.

Pigmentation changes should also not automatically be assumed to be harmless without appropriate assessment.

PT-141 and mental health

Sexual desire is closely linked with:

• Depression

• Anxiety

• Trauma

• Body image

• Medication

• Relationship health

• Stress

Bremelanotide was not approved for low desire primarily caused by a psychiatric condition.

A treatment that modifies desire does not resolve the underlying mental-health disorder.

Does PT-141 cause compulsive sexual behaviour?

Compulsive sexual behaviour was not established as a common adverse effect in the clinical programme.

However, any centrally acting substance that influences reward or motivation raises reasonable questions about behavioural responses.

Long-term evidence in populations with:

• Bipolar disorder

• Impulse-control disorders

• Substance-use disorders

• Compulsive sexual behaviour

is limited.

PT-141 vs flibanserin

Flibanserin is another medicine approved in the United States for selected women with HSDD.

They have different mechanisms and safety profiles.

Is PT-141 a recreational aphrodisiac?

The word aphrodisiac is often used commercially but is scientifically imprecise.

Bremelanotide has demonstrated effects on sexual-desire measures in a specific clinical population.

This does not establish it as a safe recreational enhancer for people without HSDD.

Product-quality concerns

A commercial vial labelled PT-141 may differ substantially from FDA-approved bremelanotide.

Important variables include:

• Correct peptide identity

• Cyclic structure

• Peptide purity

• Concentration

• Sterility

• Endotoxin content

• Counterions

• Degradation

• Storage

• Reconstitution quality

A purity result alone does not establish:

• Sterility

• Accurate concentration

• Correct formulation

• Suitability for administration

Analytical testing

High-performance liquid chromatography

HPLC can separate the main peptide from some chemical impurities and estimate purity.

Mass spectrometry

Mass spectrometry can support confirmation of molecular mass and identity.

Structural confirmation

Because bremelanotide is cyclic, appropriate analysis may be required to confirm that the intended molecular structure has formed correctly.

Sterility testing

Sterility testing assesses contamination by living microorganisms.

Endotoxin testing

Endotoxins are inflammatory bacterial components that can remain even when no living bacteria are detected.

Stability testing

Stability testing evaluates whether the peptide maintains identity and concentration under defined storage conditions.

No single laboratory result proves complete safety.

Is PT-141 prohibited by WADA?

Bremelanotide is not generally discussed as a conventional anabolic or performance-enhancing drug.

However, athletes should not assume that an unapproved peptide is permitted simply because its name is not prominent in public summaries.

WADA rules include broad categories covering peptide hormones, related substances, non-approved substances and compounds with similar biological effects.

Competitive athletes should check the current official list and obtain specialist anti-doping advice before using any experimental peptide.

Common PT-141 myths

Myth: PT-141 is approved for anyone with low libido.

Fact: The US approval applies to a narrowly defined group of premenopausal women with acquired, generalised HSDD.

Myth: PT-141 is approved for men.

Fact: It is not FDA approved for men.

Myth: PT-141 is an erectile-dysfunction medicine.

Fact: It has been researched for erectile responses but is not approved for male erectile dysfunction.

Myth: PT-141 works like sildenafil.

Fact: Bremelanotide acts mainly through central melanocortin pathways, while sildenafil acts primarily on peripheral blood-flow signalling.

Myth: PT-141 increases testosterone.

Fact: It is not an established testosterone-raising treatment.

Myth: PT-141 guarantees sexual desire.

Fact: Clinical responses vary, and average trial benefits were modest.

Myth: PT-141 guarantees orgasm.

Fact: Its trials focused mainly on desire and associated distress, not guaranteed orgasm.

Myth: PT-141 has no cardiovascular effects.

Fact: It can temporarily increase blood pressure and reduce heart rate.

Myth: Skin darkening is always temporary.

Fact: Some focal hyperpigmentation may persist.

Myth: More frequent use produces better results.

Fact: More frequent exposure may increase adverse effects without improving benefit.

Myth: FDA approval makes all PT-141 products equivalent.

Fact: Unregulated research products are not automatically equivalent to the authorised medicine.

Frequently asked questions

Is PT-141 the same as bremelanotide?

Yes. PT-141 is the research name commonly used for bremelanotide.

Is Vyleesi the same as PT-141?

Vyleesi contains bremelanotide, but it is a specific regulated formulation and delivery product.

Is PT-141 a peptide?

Yes. Bremelanotide is a synthetic cyclic heptapeptide.

How many amino acids are in PT-141?

It contains seven amino acids.

Which receptors does PT-141 activate?

It activates melanocortin receptors, with its sexual effects believed to involve primarily MC3R and MC4R.

Does PT-141 affect the brain?

Yes. Its principal sexual effects are believed to involve central nervous-system signalling.

Is PT-141 a hormone?

No. It is a synthetic melanocortin receptor agonist.

Does PT-141 increase dopamine?

It may influence downstream dopamine pathways, but it is not a direct conventional dopamine agonist.

Does PT-141 increase libido?

Clinical trials demonstrated modest improvements in sexual-desire measures in selected premenopausal women with HSDD.

Does PT-141 work in men?

It has produced erectile responses in research, but it is not approved for men and robust evidence for general male use is limited.

Does PT-141 treat erectile dysfunction?

It is not an approved erectile-dysfunction treatment.

Does PT-141 work like Viagra?

No. Viagra primarily improves peripheral blood-flow signalling, while PT-141 acts through central melanocortin pathways.

Does PT-141 increase testosterone?

It is not an established testosterone-raising treatment.

Does PT-141 increase oestrogen?

A clinically meaningful oestrogen-increasing effect has not been established.

Does PT-141 improve orgasm?

It has not been proven to guarantee or directly treat orgasm difficulties.

Does PT-141 work for antidepressant-related sexual dysfunction?

It is not approved for low desire caused by medication, and evidence remains insufficient.

Does PT-141 work after menopause?

It is not FDA approved for postmenopausal women.

Does PT-141 improve fertility?

No. It is not a fertility treatment.

Is PT-141 approved by the FDA?

Bremelanotide is FDA approved for selected premenopausal women with acquired, generalised HSDD.

Is PT-141 approved in the UK?

No.

Is PT-141 approved for sexual performance enhancement?

No.

Is PT-141 approved for men?

No.

What are the most common PT-141 side effects?

Nausea, flushing, headache, vomiting and injection-site reactions are among the commonly reported adverse effects.

Can PT-141 raise blood pressure?

Yes. Temporary blood-pressure increases are an established safety concern.

Can PT-141 lower heart rate?

A temporary reduction in heart rate may occur.

Can PT-141 cause skin darkening?

Yes. Focal hyperpigmentation can occur and may sometimes persist.

Can PT-141 cause nausea?

Yes. Nausea is the most common adverse effect in clinical trials.

Can PT-141 cause headaches?

Yes. Headache is a commonly reported adverse effect.

Can PT-141 cause an erection?

Melanocortin activation can trigger erectile responses in some men, but this does not establish it as an approved male treatment.

Can PT-141 cause priapism?

Prolonged erections are a potential concern, particularly when sexual-function compounds are combined.

Can PT-141 be combined with sildenafil?

The safety of combining unregulated PT-141 with sildenafil has not been adequately established.

Can PT-141 be combined with tadalafil?

Robust combination-safety evidence is lacking.

Can PT-141 be used with alcohol?

A controlled study did not identify a major serious interaction, but this does not prove that general combination use is risk-free.

Can PT-141 affect oral medicines?

It may delay gastric emptying and alter the absorption rate of some oral medicines.

Is PT-141 safe with high blood pressure?

The approved medicine is contraindicated in uncontrolled hypertension.

Is PT-141 safe with heart disease?

The approved medicine is contraindicated in known cardiovascular disease.

Is PT-141 safe during pregnancy?

It should not be assumed to be safe during pregnancy.

Is PT-141 safe while breastfeeding?

Adequate safety evidence is lacking.

Is PT-141 addictive?

A recognised physical-dependence syndrome has not been established, but long-term behavioural evidence remains limited.

Does PT-141 cause withdrawal?

A defined withdrawal syndrome has not been established.

Is PT-141 safe long term?

The regulated product has clinical data extending beyond the initial trials, but long-term safety of informal or repeated unregulated use remains uncertain.

Does PT-141 permanently increase libido?

No evidence demonstrates a permanent increase in sexual desire.

Is PT-141 an aphrodisiac?

It has demonstrated effects on desire in a specific clinical population, but the term aphrodisiac can misleadingly imply universal recreational effectiveness.

Is every PT-141 product the same as Vyleesi?

No. Product quality, concentration, formulation and sterility may differ substantially.

PT-141 research in context

What the evidence supports

Human evidence supports that regulated bremelanotide can produce modest improvements in sexual desire and related distress in some premenopausal women with acquired, generalised HSDD.

What the evidence suggests

Experimental evidence suggests that central melanocortin signalling can influence:

• Sexual motivation

• Female sexual desire

• Genital arousal

• Erectile responses

• Reward-associated pathways

What remains uncertain

Researchers have not established:

• Routine effectiveness in men

• Effectiveness after menopause

• Effectiveness for medication-induced sexual dysfunction

• Long-term effects of frequent exposure

• Safety of combining it with PDE5 inhibitors

• Safety in many cardiovascular populations

• Effects during pregnancy or breastfeeding

• Whether unregulated research products reproduce clinical-trial results

• Broad effectiveness in people without HSDD

Key takeaways

PT-141 and bremelanotide refer to the same synthetic cyclic melanocortin peptide.

It acts mainly through central melanocortin receptors, particularly pathways involving MC3R and MC4R.

Bremelanotide is the active ingredient in Vyleesi, which was approved by the FDA in 2019 for a specific group of premenopausal women with acquired, generalised HSDD.

It is not approved for:

• Men

• Postmenopausal women

• Erectile dysfunction

• General libido enhancement

• Sexual-performance enhancement

• Medication-induced sexual dysfunction

Phase III trials demonstrated statistically significant but generally modest improvements in sexual desire and related distress.

Important adverse effects include:

• Nausea

• Headache

• Flushing

• Temporary blood-pressure elevation

• Reduced heart rate

• Focal hyperpigmentation

• Injection-site reactions

The authorised product is contraindicated in uncontrolled hypertension and known cardiovascular disease.

PT-141 is not an authorised medicine in the United Kingdom.

Unregulated PT-141 products should not be assumed to match the identity, quality, concentration or safety of FDA-approved bremelanotide.

Glossary

Acquired HSDD: Low sexual desire that develops after a previous period of satisfactory desire.

Bremelanotide: The formal generic name for PT-141.

Cyclic peptide: A peptide in which part of the molecular chain forms a ring.

FDA: The United States Food and Drug Administration.

Generalised HSDD: Low desire occurring across situations and partners rather than in one specific context.

HSDD: Hypoactive sexual desire disorder.

Hyperpigmentation: Darkening of areas of skin or mucosal tissue.

MC3R: Melanocortin 3 receptor.

MC4R: Melanocortin 4 receptor.

Melanocortin: A family of POMC-derived signalling peptides.

PDE5 inhibitor: A medicine, such as sildenafil, that supports erectile blood flow by inhibiting phosphodiesterase type 5.

POMC: Pro-opiomelanocortin, a precursor protein from which several melanocortin peptides are produced.

Priapism: A prolonged erection requiring urgent medical assessment.

Vyleesi: The US brand name for FDA-approved bremelanotide injection.

Important notice

This article is provided for educational purposes only.

It is not intended to diagnose, treat or prevent disease or to replace advice from a qualified healthcare professional.

Bremelanotide is approved in the United States only for a narrowly defined group of premenopausal women with acquired, generalised hypoactive sexual desire disorder.

It is not approved for men, postmenopausal women, erectile dysfunction or general sexual-performance enhancement.

PT-141 is not an authorised medicine in the United Kingdom.

Although bremelanotide has undergone controlled human clinical trials, it can cause significant adverse effects, including nausea, temporary blood-pressure increases and focal hyperpigmentation. Its safety and effectiveness should not be generalised to unregulated research products.